Author: Xiaochen Yang Xingjiang Xiong Guoyan Yang Jie Wang
|
|
- Stephen Higgins
- 6 years ago
- Views:
Transcription
1 Title: Chinese Patent Medicine XueFu ZhuYu Capsule for the Treatment of Unstable Angina Pectoris: A Systematic Review of Randomized Controlled Trials Author: Xiaochen Yang Xingjiang Xiong Guoyan Yang Jie Wang PII: S (14) DOI: Reference: YCTIM 1304 To appear in: Complementary Therapies in Medicine Received date: Revised date: Accepted date: Please cite this article as: Yang X, Xiong X, Yang G, Wang J, Chinese Patent Medicine XueFu ZhuYu Capsule for the Treatment of Unstable Angina Pectoris: A Systematic Review of Randomized Controlled Trials, Complementary Therapies in Medicine (2014), This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
2 Chinese Patent Medicine XueFu ZhuYu Capsule for the Treatment of Unstable Angina Pectoris: A Systematic Review of Randomized Controlled Trials Xiaochen Yang 1#, Xingjiang Xiong 1#, Guoyan Yang 2#, Jie Wang 1* 1. Department of Cardiology, Guang anmen Hospital, China Academy of Chinese Medical Sciences, Beijing , China 2. Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing , China Abstract: Background. XueFu ZhuYu Capsule (XFZY) has been commonly used for relieving chest pain in patients with coronary heart disease (CHD). Randomized controlled trials (RCTs) on XFZY in treating unstable angina (UA) have not been systematically reviewed. Objective. This study aims to provide a PRISMA-compliant systematic review to evaluate the efficacy of XFZY in treating UA. Methods. An extensive search of 7 medical databases was performed up to June RCTs involving XFZY or combined with conventional drugs versus conventional drugs were identified. Meta-analysis was performed to evaluate the cardiovascular effects of XFZY. Rev Man 5.0 was used for data analysis. Results. 8 RCTs were included in this review. Statistical analysis of the results showed that XFZY combined with conventional drugs had significant effect on relieving angina symptoms (RR: 1.26 [1.16, 1.38]; P < ) and improving ECG (RR: 1.20 [1.04, 1.38]; P = 0.01) compared with conventional drugs alone. No severe adverse events were reported. Conclusions. XFZY combined with conventional drugs appears to have potential cardiovascular effects in treatment of UA with few adverse events. However, further rigorous designed trials are still needed. Introduction Angina pectoris, a symptom of coronary heart disease (CHD), manifests as stress-induced ischemic episodes resulting in severe chest pain [1]. When the same symptoms occur at rest or become severe, unstable angina (UA) is the diagnosis [2]. UA is an acute coronary syndrome and Corresponding author at: Department of Cardiology, Guang anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5#, Xicheng District, Beijing , China. Tel.: ; fax: addresses: wangjie_gam@yahoo.com.cn (J. Wang) # These authors contributed equally in this paper. 1 Page 1 of 14
3 should be treated as an emergency. It can increase risk of acute myocardial infarction (heart attack) and severe cardiac arrhythmias which leading to sudden death [3]. Therefore, treatment should begin as soon as possible after onset of unstable angina. The ACC/AHA guidelines support anti-ischemic therapy, antiplatelet therapy and antithrombotic therapy. Anti-ischemia therapies include nitroglycerin, beta blocker, and oxygen as required. Antiplatelet therapies include aspirin, clopidogrel, and platelet glycoprotein IIb/IIIa inhibitor. Antithrombotic therapies include heparin and low-molecular-weight heparin [4-5]. Therapeutic aims are to improve quality of life by decreasing anginal attacks and to prevent myocardial infarction and death. But not all of these drugs are useful in every form of UA, and treatment is symptomatic rather than curative [6]. The other drawbacks of current anginal medications are adverse effects and drug resistance [7]. Treatment of UA with good prognosis remains a challenging clinical issue. Chinese herbal medicine (CHM) has a 3000-year-old history with unique theories for concepts of etiology and systems of diagnosis and treatment [8]. Recently, there is a growing and sustained interest in the benefits of CHM and potential drug interactions with western medications, especially for patients with UA [9-10]. CHM has been used for activating the blood and resolving stasis in clinical practice for the treatment of UA in China. Xuefu Zhuyu Tang, a famous formula for treating Xueyu (blood stagnation), consists of rehmannia root (shengdi), peach seed (taoren), Safflower (honghua), Chinese angelica (danggui), red peony root (chishao), platycodon root (jiegeng), orange fruit (zhiqiao), hare's ear root (chaihu), Sichuan lovage root (chuanxiong), two-toothed achyranthes root (niuxi), and prepared liquorice root (gancao). Xuefu Zhuyu Tang has been made into various high standard pharmaceutical preparations such as capsule, pill, tablet, granule and oral liquid. For instance, Xuefu Zhuyu Capsule (Hong Ren Tang Pharmaceutical Co., Ltd., Tianjin, China) consists of rehmannia root (shengdi) mg, peach seed (taoren) mg, Safflower (honghua) mg, Chinese angelica (danggui) mg, red peony root (chishao) mg, platycodon root (jiegeng) mg, orange fruit (zhiqiao) mg, hare's ear root (chaihu) mg, Sichuan lovage root (chuanxiong) mg, two-toothed achyranthes root (niuxi) mg, prepared liquorice root (gancao) mg. The total dose is 2.4 g for one day. Experimental studies have shown that XFZY can increase coronary blood flow, improve the cardiac microcirculation, prevent platelet aggregation, and accommodate blood lipids [11-12]. Several studies published in China have reported that XFZY can enhance the effect of relieving of angina symptoms, decreasing the dosage of nitroglycerin and lessening side effects for patients with UA [13-16]. Liu et al [14] had undertaken meta-analysis of Chinese patent medicine XueFu ZhuYu capsule for the treatment of angina pectoris, which include stable and unstable angina pectoris trials together. However, the evidence supporting or disproving its cardiovascular effects is not robust. Our review presents a more vigorous attempt to examine the efficacy and safety of XFZY for patients with UA. Methods Search strategy Two authors (X. Yang and G. Yang) searched the following electronic databases: PubMed, the Cochrane Center Controlled Trials Register (2013), EMBASE ( ), Chinese Biomedical Literature Database (CBM, June 2013), Chinese National Knowledge Infrastructure (CNKI, 1979-June 2013), Chinese Scientific Journal Database (VIP, 1989-June 2013), and Wanfang Med 2 Page 2 of 14
4 Online Database (WMOD, June 2013). The searching terms were XueFu ZhuYu, Guan xin bing (coronary heart disease), and Bu Wen Ding Xin jiao tong (unable angina pectoris). No language restriction was applied. Types of studies Randomized controlled trials that evaluate the cardiovascular effects of XFZY for UA were included. Quasi-RCTs were not considered. Types of participants The participants who suffering from and being treated for angina pectoris were included, regardless of the disease and severity. Diagnosis of UA was according to the 2002 ACCF/AHA Guideline for the Diagnosis and Management of Patients with Unstable Ischemic Heart Disease (2002 ACCF/AHA) or the International Society and Federation of Cardiology/World Health Organization (ISFC/WHO) [17-18]. We did not intend to make any restrictions on age, gender, and race. Types of interventions The medicine of treatment group was XFZY combined with conventional drugs for patients with UA regardless of manufactures, preparation form, dose and duration. The study was designed to compare the effectiveness and safety of XFZY used only or in combination with conventional drugs versus conventional drugs alone or plus placebo. Types of outcome measures The primary outcome measures were mortality due to ischemic heart disease and the incidence of a heart event (e.g. AMI, severity arrhythmia, heart failure, revascularization). The secondary outcome measures were: (1) reduction of angina symptoms (e.g. Effective symptomatic improvements should achieve at least 50% or 80% reduction in frequency of feeling angina chest pain [18]). (2) ECG improvement (e.g. Effective ECG improvements should achieve at least 0.05mV lowering at ST segment in ECG or nearly normal ECG during an exercise test [18]), and (3) quality of life [19]. The adverse events were also measured. Study selection. The titles and abstracts of potentially relevant references were identified through the literature search and reviewed independently by 2 reviewers (X. Yang, and X. Xiong) according to predefined criteria. Discrepancies regarding whether to include or exclude a study were resolved by consensus with other investigator (J. Wang). Data extraction The following data were extracted: (1) citations (authors of study, year of publication), (2) methodological information, (3) participants (sample size, age), (4) detailed information of interventions and controls, (5) outcome measures, and (6) adverse events. Two reviewers (X. Xiong, X. Yang) checked the disagreement of data extraction. Differences in data extraction were resolved by discussion. 3 Page 3 of 14
5 Trial quality assessment Two authors (Y. Zhang, G. Yang) independently assessed the methodological quality of included RCTs using Cochrane risk of bias tool. The qualities of included RCTs were assessed according to seven specific domains: (1) random sequence generation (selection bias), (2) allocation concealment (selection bias), (3) blinding of participants and personnel (performance bias), (4) blinding of outcome data (attrition bias), (5) incomplete outcome data (attrition bias), (6) selective reporting (reporting bias), and (7) other bias. When completing each of the seven domains for a study, information was provided according to RevMan 5.0: (1) a description of included study; and (2) their judgment on the risk of bias as a consequence of this. This judgment is categorized by using one of the three answers: high risk, unclear risk and low risk. Statistical analysis Meta-analysis was performed if the intervention, control, and outcome were the same or similar. According to RevMan 5.0 provided by Cochrane Collaboration, dichotomous data were expressed as risk ratio (RR) and continuous outcomes as weighted mean difference (WMD), with their 95% confidence intervals (CI) respectively. The statistical heterogeneity was examined with the I 2 test, where I 2 values of 50% or more were considered to be indicators of a substantial level of heterogeneity. In the absence of significant heterogeneity (I 2 < 50%), we pooled data using a fixed-effect model, otherwise we using random effects model (I 2 > 50%) [20]. Result Literature search and study selection Our initial searches finally identified 610 articles according to the search strategy, among which 252 studies were excluded because of duplicated publication. After checking the abstracts, 405 articles were excluded because of non-clinical studies, with obvious error, or with study objectives different from the aim of this review, etc (Figure 1). Full texts of 53 articles were retrieved for further identification, and finally 8 RCTs [21-28] were included according to the inclusion criteria. The included RCTs were all conducted in China and published in Chinese. Characteristics of the trials included The characteristics of included RCTs were summarized in Table 1. The number of participants ranged from 28 to 50, with a total of 534 patients (265 patients in treatment groups) in the 8 studies. The age of the participants ranged from 35 years to 82 years. The studies included only interventions with XFZY plus conventional drugs versus conventional drugs alone or plus placebo. Because no RCTs of XFZY versus conventional drugs alone or plus placebo was founded. Conventional drugs referred to treatment according to the guidelines for UA, including platelet aggregation inhibitor (aspirin), nitrates, beta-blockers, calcium channel blockers, and ACE inhibitors. The total treatment duration ranged from 1 weeks to 8 weeks. Reductions in angina symptoms and improvement in ECG were the most commonly measured outcomes in the included studies. None trial adopted mortality as primary outcome. 1 trial [26] reported the quality of life of UA patients. 4 Page 4 of 14
6 Methodological Quality of Included Trials All of these studies indicated randomization with a single-center, parallel-design, but most of them did not describe it clearly. 2 trials [26, 28] reported that the random sequence was generated by a random digits table. None of trials describe allocation concealment and methods of assessing compliance. 1 trial [26] mentioned that they were single blind of subjects, but included no descriptions of the procedures. 1 trial [26] reported drop-out or withdraw, but none of trials had a pre-trial estimation of sample size, which indicated the lack of statistical power to ensure appropriate estimation of the therapeutic effect. Primary outcomes None trial adopted mortality as primary outcome. There was no report of ischemic heart disease and the incidence of a heart event (e.g. AMI, severity arrhythmia, heart failure, revascularization). Reduction of angina symptoms (RAS) A total of 7 trials [21-25, 27-28] with 477 patients used reduction of angina symptoms (RAS) to measure the outcome. It is showed homogeneity in the results (P=0.74, I 2 =0%). Thus, we did a quantitative data synthesis (meta-analysis) by fixed-effects model. The outcome shows a statistically significant difference in favor of the combination group of XFZY and conventional drugs (RR: 1.26 [1.16, 1.38]; P < ). It is suggested that XFZY plus conventional drugs had a better effect on relieving symptoms of angina. (Table 2). ECG improvement A total of 4 trials [22, 25, 27, 28] with 276 patients used ECG to measure the outcome. It is showed homogeneity in the results (P=1.2400, I 2 =0%). Thus, we did a quantitative data synthesis (meta-analysis) by fixed-effects model. The outcome shows a statistically significant difference in favor of the combination group of XFZY and conventional drugs (RR: 1.20 [1.04, 1.38]; P = 0.01). It is suggested that XFZY plus conventional drugs had a better effect on improving ECG. (Table 3). Improvement of Life Quality Two trials [26, 28] reported the improvement of life quality of patients after 4-8 weeks of treatment with XFZY combined with conventional drugs. The statistical data show that XFZY plus conventional drugs was better than conventional drugs alone with regard to relieving body symptoms (MD: 8.03 [1.12, 14.96]) and promoting anginal stability (MD: [4.61, 19.65]). Publication Bias Due to no sufficient number of trials, we failed to perform funnel plot to detect publication bias. Adverse Effect Five trials [23, 28] reported adverse effects relating to the treatment by XFZY combined with conventional drugs. The adverse effects included headache and nausea. The approximate rates of these adverse effects were 2% (6/265) and 1.5% (4/265) respectively. No severe adverse events 5 Page 5 of 14
7 were reported. Discussion This systematic review included 8 randomized trials and a total of 534 participants. The main findings of this systematic review were that XFZY combined with conventional drugs demonstrated potential effect on relieving symptoms of angina (RR: 1.26 [1.16, 1.38]; P < ) and improving ECG (RR: 1.20 [1.04, 1.38]; P = 0.01) compared to conventional drugs alone. XFZY as an adjunctive treatment to conventional drugs has good effects on treating patients with UA. However, the evidence remains weak due to the low-quality of the trials. Thus, available data are not adequate to draw a definite conclusion of combination therapy for UA. And the positive findings should be interpreted conservatively due to the following facts. Firstly, the quality of the included RCTs was generally low. (1) Randomization: all the included trials claimed randomization; however, 2 trials provided sufficient information on randomization [26, 28]. The other trials mentioned randomization but without further details, which did not allow a proper judgment of the conduct of the trials. It could lead to selection bias. (2) Blinding: only 1 trial [26] mentioned that they were single blind of subjects, but included no descriptions of the procedures. The rest studies were lack of any blinding method, either blinding of participants and personnel or blinding of outcome assessment. It could directly lead to performance bias due to patients and researchers being aware of the therapeutic interventions for the subjective outcome measures. (3) Sample size: none of trials had a pretrial estimation of sample size, which indicated the lack of statistical power to ensure appropriate estimation of the therapeutic effect. And all of the included trials were of single center. Sample size calculation should be conducted before enrollment. (4) Placebo controlled: 1 trial [26] had placebo control, which use A + B versus B + placebo of A ; however, the rest included trials used A + B versus B design which patients were randomized to receive XFZY plus conventional drugs treatment versus conventional drugs control treatment without a rigorous control for placebo effect. Consequently, positive conclusions would be draw due to nonspecific placebo effects. (5) Analysis of data: only 1 trial [26] had reported the dropouts, but without the intention-to-treat analysis. Therefore, the positive findings should be interpreted conservatively. It could lead to attrition bias. Nevertheless, there were 2 trials [25, 26] conducted by 3-7 authors. The rest 6 trials were only conducted by one or two authors. It is difficult to accomplish an RCT which including randomization, allocation concealment, blinding and analysis by less than 3 doctors. It could also lead to performance bias [29-32]. Secondly, all the included trials used reduction of angina symptoms or ECG test as the main outcomes. There were only a few trials report the original data about the frequency and duration of chest pain or reduction of nitroglycerin dose, however it was indicated a substantial level of heterogeneity of these data, and meta-analysis did not be adopt. All the RCTs claimed that the positive effect of XFZY combined with conventional drugs is better than conventional drugs alone. Negative findings almost have not been reported. We tried to conduct extensive searches for unpublished material, but no unpublished negative studies were found, which could lead to publication bias. Thirdly, patients in UA should be treated carefully because the risk of acute MI and severe cardiac arrhythmias may increase and lead to sudden death. Indeed, none of the included trials reported the mortality rate or the incidence of complications. It is likely to require longer periods 6 Page 6 of 14
8 of treatment due to the duration of included trials only ranged from 1 to 8 weeks. Moreover, the severity of angina symptoms may exacerbate without reasonable treatment, thus a longer follow-up period with serial measurements of outcomes is suggested to determine the long-term efficacy of Chinese patent medicine [33-35]. Fourthly, the safety problem of integrative medicine therapy with both conventional western medicine and tradition medicine is generally concerned [36-37]. Herb-drug interaction is an important focus of this systematic review. There were 2 trials reported the adverse effect of XFZY in combination with conventional drugs. The main adverse effects included headache (6/265) and nausea (4/265). Considering that limited report of adverse events, conclusions on the safety of XFZY could not be drawn. Generally, as the quality of 8 trials reviewed and included in meta-analysis were generally weak, further high quality trials are needed to assess the effectiveness of XFZY combined with conventional drugs in treating UA. To improve the trial design quality, future researchers should follow the basic guidelines for reporting clinical trials such as the CONSORT statement, and treatment process should be monitored rigorously and reported appropriately in the future clinical trials[38-42]. Conclusion Our systematic review suggest that XFZY in combination with conventional drugs may have good effect on reducing angina symptoms and improving ECG with few side effects for patients with UA. However, the definite conclusion cannot be drawn due to the low quality of included trials. More rigorously designed, large-sample, randomize controlled trials should be performed in the future. Conflicts of Interests All authors declare that they have no conflicts of interests. Acknowledgment The current work was partially supported by the National Basic Research Program of China (973 Program, No. 2003CB517103) and the National Natural Science Foundation Project of China (No ). Author contributions Jie Wang, X. Xiong contributed equally to this paper. Correspondence should be addressed to X. Yang (avill1988@126.com). References 1. Bernard R, Corday E, Eliasch H, and Gonin A et al, Nomenclature and Criteria for Diagnosis of Ischemic Heart Disease, The Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature, Circulation, vol. 59, pp , Braunwald E, Morrow DA, Unstable angina: is it time for a requiem? Circulation, vol. 127, pp , Rosamond W, Flegal K, and Friday G et al, Heart Disease and Stroke Statistics-2007 Update: 7 Page 7 of 14
9 A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, vol. 115, pp. e5-92, Pollack CV Jr, Braunwald E, 2007 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: implications for emergency department practice, Ann Emerg Med, vol. 51, no. 5, pp , Wiviott SD, Braunwald E, Unstable angina and non-st-segment elevation myocardial infarction: part I. Initial evaluation and management, and hospital care, Ann Emerg Med, vol. 70, no. 3, pp , Zavecz JH, Bueno O, Pharmacologic therapy of angina pectoris, J La State Med Soc, vol. 147, no. 5, pp , , Taggart D, Tailor treatment to the patient in stable angina, Practitioner, vol. 255, no. 1744, pp , K. J. Chen, H. Xu, The integration of traditional Chinese medicine and Western medicine Institute for clinical systems improvement, European Review, vol. 11, no. 2, pp , H. A. Tindle, R. B. Davis, R. S. Phillips, and D.M. Eisenberg, Trends in use of complementary and alternative medicine by US adults: , Alternative Therapies, Health and Medicine, vol. 11, no.1, pp , D. Eisenberg, Reflections on the past and future of integrative medicine from a lifelong student of the integration of Chinese and western medicine, Chinese Journal of Integrative Medicine, vol. 17, no. 1, pp. 3-5, S. Jun, W. Y. Chen, and K. J. Chen, et al, A Microarray Analysis of Angiogenesis Modulation Effect of Xuefu Zhuyu Decoction on Endothelial Cells, Chin J Intergr Med, vol. 18, no. 7, pp , Q. Y. Zhang, Q. L. Wang, and J. F. Su, et al., Angiogenesis Effects of Xuefu Zhuyu Decoction and VEGF Protein Expression of Rats with Acute Myocardial Ischemia, Chinese Journal of Information on TCM, vol. 18, no.2, pp , H. J. Cui, H. Y. He, and Z. H. Xing, Systematic Review and meta-analysis of Xuefu Zhuyu Decoction in patients with unstable angina, Journal of Emergency in Traditional Chinese Medicine, vol. 20, no.7, pp , G. H. Zheng, J. F. Chu, and J. P. Liu, Systematic Review of Xuefu Zhuyu Capsule for angina pectoris in patients with coronary heart disease, Journal of Traditional Chinese Medicine, vol. 53, no. 2, pp , X. M. Song, Meta-analysis of Xuefu Zhuyu Decoction combined with asprin and isosorbide mononitrate for angina pectoris in patients with coronary heart disease, The Journal of Practical Medicine, vol. 26, no. 14, pp , C. L. Wang, Q. W, and S. L. Wang, Meta-analysis of modefied Xuefu Zhuyu Decoction in patients with coronary heart disease, Journal of Liaoning University of TCM, vol.13, no.11, pp. 5-9, American College of Cardiology and American Heart Association, ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: Executive Summary and Recommendations, Circulation, vol. 102, pp , Page 8 of 14
10 18. Nomenclature and Criteria for Diagnosis of Ischemic Heart Disease, Report of the joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature, Circulation, vol. 3, pp , Ministry of health of the People s Republic of China, Clinical research guidelines for new traditional Chinese drug, August, 42-44, J. P. T. Higgins and S. Green, Corchrane Reviewers Handbook [updated March 2011], Review Manager (RevMan) [Computer program]. Version W. D. Qiu, C. Y. Yang, Clinical observation of Xuefu Zhuyu Decoction for unstable angina and effect of Hs-CRP in patients with coronary heart disease, Clinical Journal of Chinese Medicine, vol. 4, no. 6, pp , Z. X. Zhang, X. P. Song, Clinical observation of modified Xuefu Zhuyu Decoction for unstable angina in 50 cases, Hebei Journal of Traditional Chinese Medicine, vol. 28, no.4, pp , F. Q. Wang, Clinical observation of modified Xuefu Zhuyu Decoction for unstable angina in patients with coronary heart disease, Journal of Changchun University of Traditional Chinese Medicine, vol. 27, no. 1, pp , B. R. Zhao, J. P. Feng, and Q. Qin, et al, Protective Effect of Xuefu Zhuyu Capsule for endothelial cells due to angina pectoris in patients with coronary heart disease, National General Medical Journal of China, vol. 3, no. 9, pp , Y. R. Li, H. F. Zhang, and J. Du, et al, Clinical observation of Xuefu Zhuyu Capsule for unstable angina in patients with coronary heart disease, Journal of Liaoning University of Traditional Chinese Medicine, vol. 10, no. 11, pp , F. Y. Chu, J. Wang, and K. W. Yao, et al, Effect of Xuefu Zhuyu Capsule on the Symptoms and Signs and Health-related Quality of Life in the Unstable Angina Patients with Blood-stasis Syndrome after Percutaneous Coronary Intervention: A Randomized Controlled Trial, Chin J Intergr Med, vol. 16, no. 5, pp , X. Y. Wang, Y. Lou, Combination of Xuefu Zhuyu Decoction with western medicine for unstable angina in 56 cases with coronary heart disease, Tianjin Journal of Traditional Chinese Medicine, vol. 26, no. 6, pp. 521, G. L. Zheng, S. H. Wang, Clinical Effect and Mechanism of Xuefu Zhuyu Capsule in Treating Unstable Angina Pectoris, Chinese Journal of Integrated Traditional and Western Medicine, vol. 29, no. 1, pp , Wang Q, Wu T, Chen X, et al., Puerarin injection for unstable angina pectoris, Cochrane Database Syst Rev, vol. 19, no. 3, CD004196, Andraws R, Berger JS, Brown DL, Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials, Cochrane Database Syst Rev, vol. 293, no. 21, pp , Zhang JH, Shang HC, Gao XM, et al., Compound Salvia droplet pill, a traditional Chinese medicine, for the treatment of unstable angina pectoris: a systematic review, Med Sci Monit, vol. 14, no. 1, pp. 1-7, Wu T, Harrison RA, Chen X, et al., Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris, Cochrane Database Syst Rev, vol. 18, no. 4, CD004474, Wang J, Yang X, Chu F, et al., The effects of xuefu zhuyu and shengmai on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris after 9 Page 9 of 14
11 percutaneous coronary intervention: a randomised controlled clinical trial, Evid Based Complement Alternat Med, 2013: doi: /2013/896467, Wang J, Yang X, Feng B, et al., Is yangxue qingnao granule combined with antihypertensive drugs, a new integrative medicine therapy, more effective than antihypertensive therapy alone in treating essential hypertension?, Evid Based Complement Alternat Med, 2013: doi: /2013/540613, Wang J, Yao K, Yang X, et al., Chinese patent medicine liu wei di huang wan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of randomized controlled trials, Evid Based Complement Alternat Med, 2012: doi: /2012/714805, Food and Drug Administration of the People's Republic of China, Guidelines for clinical research in treatment of Qi stagnation of Chest with Chinese medicine (Angina pectoris)- Guidelines for clinical research with Chinese medicine/new medicine, China Medical Science and Technology Press, pp , J. Hu, J. H. Zhang, and W. Zhao, et al., Cochrane systematic reviews of Chinese herbal medicines: an overview, Plos one, vol. 6, pp. 1371, Turner L, Shamseer L, Altman DG, et al., Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review, Syst Rev, vol. 1, no. 60, doi: / , Turner L, Shamseer L, Altman DG, et al., Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals, Cochrane Database Syst Rev, vol. 14, no. 11, doi: / , X. J. Xiong, X. C. Yang, W. Liu, B. Feng, J. Z. Ma, X. L. Du, P. Q. Wang, F. Y. Chu, J. Li, and J. Wang, Banxia baizhu tianma decoction for essential hypertension: a systematic review of randomized controlled trials, Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID , 10 pages, doi: /2012/ X. J. Xiong, X. C. Yang, B. Feng, W. Liu, L. Duan, A. Gao, H. X. Li, J. Z. Ma, X. L. Du, N. Li, P. Q. Wang, K. L. Su, F. Y. Chu, G. H. Zhang, X. K. Li, and J. Wang, Zhen gan xi feng decoction, a traditional Chinese herbal formula, for the treatment of essential hypertension: a systematic review of randomized controlled trials, Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID , 9 pages, Smith SM, Chang RD, Pereira A, et al., Adherence to CONSORT harms-reporting recommendations in publications of recent analgesic clinical trials: an ACTTION systematic review, Pain, vol. 153, no. 12, pp , Page 10 of 14
12 Included Eligibility Screening Identification Records identified through database searching (n =609) Records after duplicates removed (n =252) Records screened (n =458) Full-text articles assessed for eligibility (n =53) Studies included in meta-analysis (n =8) Additional records identified through other sources (n = 1) Figure 1. Flow-chart of Study Search and Selection Records excluded (n =405) Full-text articles excluded, with reasons (n =45): Non RCTs (n =3) Duplicated publication (n =3) Diagnosis uncertainty (n =8) Inappropriate control (n =15) Ineligible data extraction (n =5) Patients complicated with serious medical conditions (n =11) 11 Page 11 of 14
13 Table1. The characteristics of included RCTs of XFZY for UA Study ID Sample Diagnosis Age Intervention Control Course Outcome (T/C) standard group group (week) measures Qiu and Yang 2012 [21] Zhang and Song 2006 [22] 30/ XFZY+conventional drugs conventional drugs 2 RAS ISFC/WHO 50/ XFZY conventional drugs 3 RAS, ECG ACCF/AHA Accepted Manuscrip Notes: XFZY: XueFu Zhuyu Capsule; RAS: Reduction of angina symptoms + conventional drugs Wang 2011 [23] 40/ ±8.3 XFZY conventional drugs 4 RAS, ACCF/AHA + conventional drugs adverse event Zhao et al [24] 30/ XFZY conventional drugs 1 RAS Li et al 2008 [25] Chu et al 2009 [26] ISFC/WHO + conventional drugs 30/ XFZY + isosorbide isosorbide dinitrate, 4 RAS, ECG ACCF/AHA dinitrate, aspirin aspirin 28/ XFZY conventional drugs 4 RAS, ACCF/AHA + conventional drugs + placebo of XFZY Life quality Wang and Lou 28/ Not clear XFZY conventional drugs 2 RAS, ECG, 2009 [27] Zheng and Wang 2009 [28] ISFC/WHO 30/ ISFC/WHO + conventional drugs XFZY conventional drugs 8 RAS, ECG + conventional drugs 1 Page 12 of 14
14 Table 2. Analyses of reduction of angina symptoms Trials Intervention (n/n) Control (n/n) RR [95% CI] P Value XFZY plus conventional drugs versus conventional drugs 1 26/30 19/ [1.01, 1.86] 0.04 XFZY plus conventional drugs versus conventional drugs 1 47/50 41/ [0.99, 1.33] 0.07 XFZY plus conventional drugs versus conventional drugs 1 37/40 30/ [1.01, 1.51] 0.04 XFZY plus conventional drugs versus conventional drugs 1 28/30 21/ [1.06, 1.79] 0.02 XFZY plus isosorbide dinitrate and aspirin versus isosorbide dinitrate and aspirin Accepted Manuscrip 1 28/30 24/ [0.95, 1.43] 0.14 XFZY plus conventional drugs versus conventional drugs 1 25/28 18/ [1.02, 1.88] 0.03 XFZY plus conventional drugs versus conventional drugs 1 28/30 21/ [1.04, 1.72] 0.03 Table 3. Analyses of improvement of ECG Trials Intervention (n/n) Control (n/n) RR [95% CI] P Value XFZY plus conventional drugs versus conventional drugs 1 36/50 30/ [0.90, 1.60] 0.21 XFZY plus isosorbide dinitrate and aspirin versus isosorbide dinitrate and aspirin 1 27/30 23/ [0.93, 1.48] 0.17 XFZY plus conventional drugs versus conventional drugs 1 24/28 20/ [0.91, 1.59] 0.20 XFZY plus conventional drugs versus conventional drugs 1 23/30 19/ [0.86, 1.69] Page 13 of 14
15 Conflicts of Interests All authors declare that they have no conflicts of interests. 3 Page 14 of 14
Review Article Xuesaitong Soft Capsule (Chinese Patent Medicine) for the Treatment of Unstable Angina Pectoris: A Meta-Analysis and Systematic Review
Evidence-Based Complementary and Alternative Medicine Volume 2013, Article ID 948319, 7 pages http://dx.doi.org/10.1155/2013/948319 Review Article Xuesaitong Soft Capsule (Chinese Patent Medicine) for
More informationDepartment of Cardiology, Guang anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange No. 5, Xicheng District, Beijing , China
Evidence-Based Complementary and Alternative Medicine, Article ID 976713, 9 pages http://dx.doi.org/10.1155/2014/976713 Review Article Shen Song Yang Xin Capsule Combined with Antiarrhythmic Drugs, a New
More informationResearch Article Systematic Review of Chinese Herbal Medicines for Preventing in-stent Coronary Restenosis after Percutaneous Coronary Intervention
Evidence-Based Complementary and Alternative Medicine Volume 2012, Article ID 253409, 19 pages doi:10.1155/2012/253409 Research Article Systematic Review of Chinese Herbal Medicines for Preventing in-stent
More informationEfficacy of Ligustrazine Injection as Adjunctive Therapy for Angina Pectoris: A Systematic Review and Meta-Analysis
META-ANALYSIS e-issn 1643-3750 DOI: 10.12659/MSM.895362 Received: 2015.07.16 Accepted: 2015.08.27 Published: 2015.11.29 Efficacy of Ligustrazine Injection as Adjunctive Therapy for Angina Pectoris: A Systematic
More informationMonth/Year of Review: November 2014 Date of Last Review: June 2012 PDL Classes: Anti-anginals, Cardiovascular
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationState Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Taipa , Macau 2
Evidence-Based Complementary and Alternative Medicine Volume 2012, Article ID 904147, 8 pages doi:10.1155/2012/904147 Research Article Meta-Analysis of Randomized Controlled Trials on the Efficacy of Di
More informationClinical study of Huxinkang tablet in treating unstable angina pectoris
ISSN : 0974-7435 Volume 10 Issue 17 BTAIJ, 10(17), 2014 [9538-9543] Clinical study of Huxinkang tablet in treating unstable angina pectoris Wang Guoqian 1, Yu Zhengke 2, Cheng Zhihong 2, Xie hongtu 3 1
More informationCell Physiol Biochem 2016;39: DOI: / Huang et al.: Clinical Effects of Aspirin in Combination with FDD
Original Paper 2016 The Author(s). 2016 Published The Author(s) by S. Karger AG, Basel Published online: October 24, 24, 2016 2016 Published by S. Karger AG, Basel 1955 Accepted: August 17, 2016 This article
More informationA Chinese Patent Medicine for the Secondary Prevention of Myocardial Infarction
Section 1 01 Clinical Trials A Chinese Patent Medicine for the Secondary Prevention of Myocardial Infarction China Boli Zhang and Junhua Zhang. Tianjin University of Traditional Chinese Medicine, 312 Anshanxi
More informationReview Article An Overview of Systematic Reviews of Danhong Injection for Ischemic Stroke
Evidence-Based Complementary and Alternative Medicine Volume 2016, Article ID 8949835, 7 pages http://dx.doi.org/10.1155/2016/8949835 Review Article An Overview of Systematic Reviews of Danhong Injection
More informationAcupuncture therapy for angina pectoris: a systematic review
Online Submissions: http://www.journaltcm.com J Tradit Chin Med 2012 December 15; 32(4): 494-501 info@journaltcm.com ISSN 0255-2922 2012 JTCM. All rights reserved. EVIDENCE-BASED STUDY Acupuncture therapy
More informationMeta-Analysis of Randomized Controlled Trial in Treating Primary Liver Cancer by Fufang Kushen Injection Combined with TACE
4th International Conference on Sustainable Energy and Environmental Engineering (ICSEEE 2015) Meta-Analysis of Randomized Controlled Trial in Treating Primary Liver Cancer by Fufang Kushen Injection Combined
More informationSchool of Dentistry. What is a systematic review?
School of Dentistry What is a systematic review? Screen Shot 2012-12-12 at 09.38.42 Where do I find the best evidence? The Literature Information overload 2 million articles published a year 20,000 biomedical
More informationResearch Article Clinical and Epidemiological Investigation of TCM Syndromes of Patients with Coronary Heart Disease in China
Evidence-Based Complementary and Alternative Medicine Volume 2012, Article ID 714517, 5 pages doi:10.1155/2012/714517 Research Article Clinical and Epidemiological Investigation of TCM Syndromes of Patients
More informationEffectiveness of Balance Acupuncture for the Pain in. Neck-Shoulder-Low back-legs: A Meta-Analysis
Hou-Lian WANG et al./journal of Acupuncture and Herbs 1 (201)9-1 9 Effectiveness of Balance Acupuncture for the Pain in Neck-Shoulder-Low back-legs: A Meta-Analysis Hou-Lian WANG a, An-Lin GUO a, Jun-Yun
More informationReview Article Xuezhikang Capsule for Type 2 Diabetes with Hyperlipemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trails
Evidence-Based Complementary and Alternative Medicine Volume 2015, Article ID 468520, 13 pages http://dx.doi.org/10.1155/2015/468520 Review Article Xuezhikang Capsule for Type 2 Diabetes with Hyperlipemia:
More informationThis Sense, other Interventions that Focus on the Strengthening of. the Co-Parenting Relationship are Recommended
ISSN: 2576-4772 This Sense, other Interventions that Focus on the Strengthening of the Co-Parenting Relationship are Recommended Liping Ma, Haiyong Chen, YanboZhang and WeiMeng* Hong Kong Branch of zhu
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More informationEffectiveness and safety of ShenXiong glucose injection for acute ischemic stroke: a systematic review and GRADE approach
Liu et al. BMC Complementary and Alternative Medicine (2016) 16:68 DOI 10.1186/s12906-016-1038-8 RESEARCH ARTICLE Open Access Effectiveness and safety of ShenXiong glucose injection for acute ischemic
More informationTraditional Chinese Herbal Medicine for Perimenopausal Depression of Chinese Women: A Meta analysis
Download free from www.wjtcm.net Review Article Traditional Chinese Herbal Medicine for Perimenopausal Depression of Chinese Women: A Meta analysis Ying Zhang a, Lin-Jie Xu b, Yu Zheng c, Feng-Quan Xu
More informationResearch Article A Meta-Analysis of Randomized Controlled Trials on Acupuncture for Amblyopia
Evidence-Based Complementary and Alternative Medicine Volume 2013, Article ID 648054, 6 pages http://dx.doi.org/10.1155/2013/648054 Research Article A Meta-Analysis of Randomized Controlled Trials on Acupuncture
More informationSystematic review: The effectiveness and safety of diclofenac for the. pain management after cesarean
Systematic review: The effectiveness and safety of diclofenac for the pain management after cesarean ABSTRACT This is the protocol of systematic review and there is no abstract. The objective is to evaluate
More informationReview Article The Efficacy of Guanxinning Injection in Treating Angina Pectoris: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Evidence-Based Complementary and Alternative Medicine Volume 2013, Article ID 282707, 16 pages http://dx.doi.org/10.1155/2013/282707 Review Article The Efficacy of Guanxinning Injection in Treating Angina
More informationCLINICAL INVESTIGATION OF ANTI-ANGINAL MEDICINAL PRODUCTS IN STABLE ANGINA PECTORIS
CLINICAL INVESTIGATION OF ANTI-ANGINAL MEDICINAL PRODUCTS IN STABLE ANGINA PECTORIS Guideline Title Clinical Investigation of Anti-Anginal Medicinal Products in Stable Angina Pectoris Legislative basis
More informationAnginal pain is a result of an imbalance between myocardial oxygen supply and demand. Pharmacological management is aimed at prevention of myocardial
Angina Anginal pain is a result of an imbalance between myocardial oxygen supply and demand. Pharmacological management is aimed at prevention of myocardial ischemia and pain as well as prevention of myocardial
More informationSalvianolate injection in the treatment of unstable angina pectoris A systematic review and meta-analysis
Systematic Review and Meta-Analysis Medicine Salvianolate injection in the treatment of unstable angina pectoris A systematic review and meta-analysis Dan Zhang, MM, Jiarui Wu, MD, PhD, Shi Liu, MM, Xiaomeng
More informationLiu Jing and Liu Jing Diagnosis System in Classical TCM Discussions of Six Divisions or Six Confirmations Diagnosis System in Classical TCM Texts
Liu Jing and Liu Jing Diagnosis System in Classical TCM Discussions of Six Divisions or Six Confirmations Diagnosis System in Classical TCM Texts Liu Jing Bian Zheng system had developed about 1800 years
More informationSystematic Review & Course outline. Lecture (20%) Class discussion & tutorial (30%)
Systematic Review & Meta-analysisanalysis Ammarin Thakkinstian, Ph.D. Section for Clinical Epidemiology and Biostatistics Faculty of Medicine, Ramathibodi Hospital Tel: 02-201-1269, 02-201-1762 Fax: 02-2011284
More informationANGINA PECTORIS. angina pectoris is a symptom of myocardial ischemia in the absence of infarction
Pharmacology Ezra Levy, Pharm.D. ANGINA PECTORIS A. Definition angina pectoris is a symptom of myocardial ischemia in the absence of infarction angina usually implies severe chest pain or discomfort during
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationEffectiveness of reinforcing kidney and activating blood therapy for premature ovarian failure: a systematic review and meta-analysis.
Biomedical Research 2018; 29 (21): 3888-3895 ISSN 0970-938X www.biomedres.info Effectiveness of reinforcing kidney and activating blood therapy for premature ovarian failure: a systematic review and meta-analysis.
More informationJie Wang, 1 Xingjiang Xiong, 1 Guoyan Yang, 2 Yuqing Zhang, 3 Yongmei Liu, 1 Yun Zhang, 1 Zhenpeng Zhang, 1 Jun Li, 1 and Xiaochen Yang 1
Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2013, Article ID 262685, 10 pages http://dx.doi.org/10.1155/2013/262685 Review Article Chinese Herbal Medicine
More informationResults. NeuRA Herbal medicines August 2016
Introduction have been suggested as a potential alternative treatment which may positively contribute to the treatment of schizophrenia. Herbal therapies can include traditional Chinese medicines and Indian
More informationControlled Trials. Spyros Kitsiou, PhD
Assessing Risk of Bias in Randomized Controlled Trials Spyros Kitsiou, PhD Assistant Professor Department of Biomedical and Health Information Sciences College of Applied Health Sciences University of
More informationAcupuncture for Depression?: A Systematic Review of Systematic Reviews
Acupuncture for Depression?: A Systematic Review of Systematic Reviews Evaluation & the Health Professions 34(4) 403-412 ª The Author(s) 2011 Reprints and permission: sagepub.com/journalspermissions.nav
More informationReview Article The Effectiveness and Safety of Acupuncture for Patients with Chronic Urticaria: A Systematic Review
BioMed Research International Volume 2016, Article ID 5191729, 7 pages http://dx.doi.org/10.1155/2016/5191729 Review Article The Effectiveness and Safety of Acupuncture for Patients with Chronic Urticaria:
More informationQigong for healthcare: an overview of systematic reviews
RESEARCH Qigong for healthcare: an overview of systematic reviews Myeong Soo 1,2 Byeongsang Oh 3 Edzard Ernst 2 1 Brain Disease Research Centre, Institute of Oriental Medicine, Daejeon, South 2 Complementary
More informationMedicine Dr. Omed Lecture 2 Stable and Unstable Angina
Medicine Dr. Omed Lecture 2 Stable and Unstable Angina Risk stratification in stable angina. High Risk; *post infarct angina, *poor effort tolerance, *ischemia at low workload, *left main or three vessel
More informationTRANSPARENCY COMMITTEE OPINION. 4 November 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 November 2009 RANEXA 375 mg extended release tablet Pack of 60 (CIP: 394 370-7) RANEXA 500 mg extended release tablet
More informationAcupuncture combined with herbal medicine versus herbal medicine alone for plaque psoriasis: a systematic review protocol
Study Protocol Page 1 of 6 Acupuncture combined with herbal medicine versus herbal medicine alone for plaque psoriasis: a systematic review protocol Shiju Xiao 1,2, Bo Li 3, Shuo Feng 3, Cunzhi Liu 4,
More informationJournal of Ethnopharmacology
Journal of Ethnopharmacology 140 (2012) 555 567 Contents lists available at SciVerse ScienceDirect Journal of Ethnopharmacology journa l h o me page: www.elsevier.com/locate/jethpharm Comparison of effectiveness
More informationMeta-analyses: analyses:
Meta-analyses: analyses: how do they help, and when can they not? Lee Hooper Senior Lecturer in research synthesis & nutrition l.hooper@uea.ac.uk 01603 591268 Aims Systematic Reviews Discuss the scientific
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationYi-Long Yang 1, Guo-Yuan Sui 1, Guang-Cong Liu 2, De-Sheng Huang 3, Si-Meng Wang 4 and Lie Wang 1*
Yang et al. BMC Cancer 2014, 14:956 RESEARCH ARTICLE Open Access The effects of psychological interventions on depression and anxiety among Chinese adults with cancer: a meta-analysis of randomized controlled
More informationSystematic review of long-term Xingnao Kaiqiao needling efficacy in ischemic stroke treatment
NEURAL REGENERATION RESEARCH April 2015,Volume 10,Issue 4 www.nrronline.org Systematic review of long-term Xingnao Kaiqiao needling efficacy in ischemic stroke treatment Zhi-xin Yang 1, *, Jia-hong Xie
More informationExecutive Summary. Different antihypertensive drugs as first line therapy in patients with essential hypertension 1
IQWiG Reports Commission No. A05-09 Different antihypertensive drugs as first line therapy in patients with essential hypertension 1 Executive Summary 1 Translation of the executive summary of the final
More informationInvestigation for quality of claimed randomised controlled trials published in China
Investigation for quality of claimed randomised controlled trials published in China Chinese Cochrane Centre Wu Taixiang, Li Youping, Liu Guanjian, etc Chinese Cochrane Centre, West China University, Sichuan
More informationConstruction of the Vesselcollateral. Guidance for Prevention and Treatment of Vasculopathy. Section 1. China. Clinical Trials.
Section 1 05 Clinical Trials Construction of the Vesselcollateral Theory and its Guidance for Prevention and Treatment of Vasculopathy China Yiling Wu The Integration of Traditional and Western Medical
More informationLiwei Shi 1,2, Yanming Xie 1, Xing Liao 1*, Yan Chai 3 and Yanhua Luo 1,2
Shi et al. BMC Complementary and Alternative Medicine (2015) 15:418 DOI 10.1186/s12906-015-0939-2 RESEARCH ARTICLE Shenmai injection as an adjuvant treatment for chronic cor pulmonale heart failure: a
More informationDrug Class Literature Scan: Antianginals
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFeng-Yi Lai, RN, MSN, Instructor Department of Nursing, Shu-Zen College of Medicine and Management, Asphodel Yang, RN, PhD, Associate Professor
Feng-Yi Lai, RN, MSN, Instructor Department of Nursing, Shu-Zen College of Medicine and Management, Asphodel Yang, RN, PhD, Associate Professor Department of Nursing, Central Taiwan University of Science
More informationInitial Medical and Surgical Management of Unstable Angina Pectoris
Clin. Cardiol. 2. 311-316 (I979) G. Witzstrock Publishing House. Inc. Editorial Initial Medical and Surgical Management of Unstable Angina Pectoris Introduction The purpose of this report is to review
More informationDATE: 04 April 2012 CONTEXT AND POLICY ISSUES
TITLE: Procedure Site Bleeding Complications Following Percutaneous Coronary Interventions or Angioplasty: A Review of Clinical Evidence and Guidelines DATE: 04 April 2012 CONTEXT AND POLICY ISSUES Percutaneous
More informationCholesterol lowering intervention for cardiovascular prevention in high risk patients with or without LDL cholesterol elevation
TrialResults-center.org www.trialresultscenter.org Cholesterol lowering intervention for cardiovascular prevention in high risk patients with or without LDL cholesterol elevation A systematic review and
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Search terms*
Supplementary Figure S1. Search terms* *mh = exploded MeSH: Medical subject heading (Medline medical index term); tw = text word; pt = publication type; the asterisk (*) stands for any character(s) #1:
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Percutaneous access for endovascular aortic aneurysm repair: a systematic review and meta-analysis Shahin Hajibandeh, Shahab Hajibandeh,
More informationReview Article Compound Danshen Dripping Pill for Treating Nonproliferative Diabetic Retinopathy: A Meta-Analysis of 13 Randomized Controlled Trials
Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2017, Article ID 4848076, 10 pages https://doi.org/10.1155/2017/4848076 Review Article Compound Danshen Dripping Pill for Treating Nonproliferative
More informationManagement of new onset atrial fibrillation McNamara R L, Bass E B, Miller M R, Segal J B, Goodman S N, Kim N L, Robinson K A, Powe N R
Management of new onset atrial fibrillation McNamara R L, Bass E B, Miller M R, Segal J B, Goodman S N, Kim N L, Robinson K A, Powe N R Authors' objectives To synthesise the evidence that exists to guide
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationIntroduction. Original Article. Abstract. Download free from
Download free from www.wjtcm.net Original Article Kangfuxin (Periplaneta americana) Lotion for Adjunctive Treatment of Ulcerative Colitis: A Systematic Review and Meta Analysis of Randomized Controlled
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationCompound salvia pellet, a traditional Chinese medicine, for the treatment of chronic stable angina pectoris compared with nitrates: a meta-analysis
Med Sci Monit, 2006; 2(): -7 PMID: 636979 WWW.MEDSCIMONIT.COM Received: 2005.0.0 Accepted: 2005.09.0 Published: 2005.2.22 Authors Contribution: A Study Design B Data Collection C Statistical Analysis D
More informationReview Article Chinese Herbal Medicine for the Treatment of Prehypertension
Evidence-Based Complementary and Alternative Medicine Volume 2013, Article ID 493521, 9 pages http://dx.doi.org/10.1155/2013/493521 Review Article Chinese Herbal Medicine for the Treatment of Prehypertension
More informationSupplementary Information for Duration of dual antiplatelet therapy after drug-eluting stent
Supplementary Information for Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials Title of manuscript: Duration of dual antiplatelet
More informationCADTH Therapeutic Review
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Therapeutic Review August 2012 Volume 1, Issue 1A Antithrombotic Therapy for
More informationEffectiveness of acupuncture for angina pectoris: a systematic review of randomized controlled trials
Yu et al. BMC Complementary and Alternative Medicine (2015) 15:90 DOI 10.1186/s12906-015-0586-7 RESEARCH ARTICLE Open Access Effectiveness of acupuncture for angina pectoris: a systematic review of randomized
More informationReliability of Echocardiography Measurement of Patent Ductus Arteriosus Minimum Diameter: A Meta-analysis
International Journal of Cardiovascular and Cerebrovascular Disease 4(): 15-19, 016 DOI: 10.13189/ijccd.016.04001 http://www.hrpub.org Reliability of Echocardiography Measurement of Patent Ductus Arteriosus
More informationDownloaded from:
Arnup, SJ; Forbes, AB; Kahan, BC; Morgan, KE; McKenzie, JE (2016) The quality of reporting in cluster randomised crossover trials: proposal for reporting items and an assessment of reporting quality. Trials,
More informationLearning from Systematic Review and Meta analysis
Learning from Systematic Review and Meta analysis Efficacy and Safety of Antiscabietic Agents: A Systematic Review and Network Meta analysis of Randomized Controlled Trials KUNLAWAT THADANIPON, MD 4 TH
More informationCritical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto
Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death Debra Moy Faculty of Pharmacy University of Toronto Goal To provide practitioners with a systematic approach to evaluating a meta analysis
More informationA nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD
The Association of Clinical Symptomatic Hypoglycemia with Cardiovascular Events and Total Death in Type 2 Diabetes Mellitus A nationwide population-based study Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD Taipei
More informationAngina Pectoris. Edward JN Ishac, Ph.D. Smith Building, Room
Angina Pectoris Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus of Virginia Commonwealth University
More informationCochrane Pregnancy and Childbirth Group Methodological Guidelines
Cochrane Pregnancy and Childbirth Group Methodological Guidelines [Prepared by Simon Gates: July 2009, updated July 2012] These guidelines are intended to aid quality and consistency across the reviews
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationEMPEROR'S COLLEGE MTOM COURSE SYLLABUS HERB FORMULAE I
COURSE DESCRIPTION The first of three courses in the Herb Formulae series. These courses can be taken in any order. The Herb Formulae series analyzes the functions, ingredients, and properties of approximately
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationZhengtao Liu 1,2,3*, Shuping Que 4*, Lin Zhou 1,2,3 Author affiliation:
Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: AMeta-analysis of Prospective Studies Zhengtao Liu 1,2,3*, Shuping Que 4*, Lin Zhou
More informationCOMPARATIVE ANALGESIC AND ANTI-INFLAMMATORY EFFECT OF ANGELICA SINENSIS PIECES AND ITS PRODUCTS IN MICE
: 1877-1883 ISSN: 2277 4998 COMPARATIVE ANALGESIC AND ANTI-INFLAMMATORY EFFECT OF ANGELICA SINENSIS PIECES AND ITS PRODUCTS IN MICE WENJUAN W 1, DANDAN C 1, YINGYING Z 2, HONGMENG Z 3 AND DEMIN G 1* 1:
More informationReview Article Moxibustion for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis
Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2017, Article ID 9854893, 11 pages https://doi.org/10.1155/2017/9854893 Review Article Moxibustion for Chemotherapy-Induced Nausea and
More informationStable Angina. Conservative Vs Intervention
Stable Angina Chittagong Medical College Hospital Conservative Vs Intervention DR MA SATTAR Associate Professor (Medicine) Chittagong Medical College, Bangladesh Background Coronary artery disease (CAD)
More informationAn example of a systematic review and meta-analysis
An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy
More information1. Introduction. Correspondence should be addressed to Xingjiang Xiong; and Jie Wang;
Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2013, Article ID 982380, 9 pages http://dx.doi.org/10.1155/2013/982380 Research Article Zhen Gan Xi Feng Decoction,
More informationDrug Class Review on Calcium Channel Blockers FINAL REPORT
Drug Class Review on Calcium Channel Blockers FINAL REPORT September 2003 TABLE OF CONTENTS Introduction 5 Scope and Key Questions 6 Methods 6 Literature Search 6 Study Selection 6 Data Abstraction 7 Validity
More informationDepartment of Acupuncture and Neurology, Guang anmen Hospital, China Academy of Chinese Medical Sciences, Beijing , China;
Review Article Page 1 of 8 Assessment of methodological quality of systematic reviews of acupuncture for chronic prostatitis/chronic pelvic pain symptom: an overview of systematic review Zongshi Qin 1,
More informationAcupuncture Outmatches Drug For IBS
Acupuncture Outmatches Drug For IBS Published by HealthCMi on December 2017 Acupuncture and Chinese herbal medicine are found effective for the alleviation of IBS (irritable bowel syndrome). Two independent
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Review title and timescale 1 Review title Give the working title of the review. This must be in English. Ideally it should state succinctly
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Closed reduction methods for acute anterior shoulder dislocation [Cochrane Protocol] Kanthan Theivendran, Raj Thakrar, Subodh Deshmukh,
More informationMeta Analysis. David R Urbach MD MSc Outcomes Research Course December 4, 2014
Meta Analysis David R Urbach MD MSc Outcomes Research Course December 4, 2014 Overview Definitions Identifying studies Appraising studies Quantitative synthesis Presentation of results Examining heterogeneity
More information24 h. P > h. R doi /j. issn
38 4 2015 4 Vol. 38 No. 4 Apr. 2015 Journal of Beijing University of Traditional Chinese Medicine 271 2 ~ 3 * 1 2 2 2 2 2 1# 1 201203 2 2 ~ 3 55 2 18 37 24 2 0 8 16 24 24 h 2 P > 0. 05 P < 0. 05 P < 0.
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2018 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationCorrespondence should be addressed to Xiaochen Yang;
Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2014, Article ID 473038, 7 pages http://dx.doi.org/10.1155/2014/473038 Review Article Is It a New Approach for
More informationAccepted Manuscript. Commentary: The Power under Control of Meta-Analysis in the Synthesis of Clinical Knowledge. Luca Bertolaccini, MD PhD FCCP
Accepted Manuscript Commentary: The Power under Control of Meta-Analysis in the Synthesis of Clinical Knowledge Luca Bertolaccini, MD PhD FCCP PII: S0022-5223(19)30273-9 DOI: https://doi.org/10.1016/j.jtcvs.2019.01.062
More informationExhibit EP16.h University of Virginia Medical Center Clinical Decision Tool
TITLE: Emergency Management for Suspicion of Cardiac Event PURPOSE: Increasingly, patients have multiple morbidities and are at risk of adverse events related or unrelated to the condition for which they
More informationTraditional Chinese Medicine syndrome patterns and Qi-regulating, chest-relaxing and blood-activating therapy on cardiac syndrome X
Online Submissions:http://www.journaltcm.com J Tradit Chin Med 2013 April 15; 33(2): 194-199 info@journaltcm.com ISSN 0255-2922 2013 JTCM. All rights reserved. CLINICAL STUDY TOPIC Traditional Chinese
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Effectiveness of collaborative care in patients with combined physical disorders and depression or anxiety disorder: a systematic review
More information